A new perspective on metformin therapy in type 1 diabetes

Livingstone, R. , Boyle, J. G. and Petrie, J. R. (2017) A new perspective on metformin therapy in type 1 diabetes. Diabetologia, 60(9), pp. 1594-1600. (doi:10.1007/s00125-017-4364-6) (PMID:28770327)

[img]
Preview
Text
143575.pdf - Published Version
Available under License Creative Commons Attribution.

469kB

Abstract

Metformin is quite frequently used off-label in type 1 diabetes to limit insulin dose requirement. Guidelines recommend that it can improve glucose control in those who are overweight and obese but evidence in support of this is limited. Recently-published findings from the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial suggest that metformin therapy in type 1 diabetes can reduce atherosclerosis progression, weight and LDL-cholesterol levels. This provides a new perspective on metformin therapy in type 1 diabetes and suggests a potential role for reducing the long-term risk of cardiovascular disease.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Boyle, Dr James and Livingstone, Dr Rachel and Petrie, Professor John
Authors: Livingstone, R., Boyle, J. G., and Petrie, J. R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Diabetologia
Publisher:Springer
ISSN:0012-186X
ISSN (Online):1432-0428
Published Online:02 August 2017
Copyright Holders:Copyright © 2017 The Authors
First Published:First published in Diabetologia 60(9):1594-1600
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
560151REMOVAL study: REducing with Metformin microvascular Outcomes and VAscular complications in T1DMJohn PetrieJuvenile Diabetes Foundation (JUVDIAFO)17-2011-272RI CARDIOVASCULAR & MEDICAL SCIENCES